Details of Disease

General Information of Disease (ID: DISU61YW)

Disease Name Thrombocytopenia
Synonyms thrombocytopenic disorder; platelet count decreased
Disease Class 3B64: Thrombocytopenia
Definition A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.
Disease Hierarchy
DISOOSU2: Blood platelet disease
DISU61YW: Thrombocytopenia
ICD Code
ICD-11
ICD-11: 3B64
Expand ICD-9
287.3,287.4,287.5
Disease Identifiers
MONDO ID
MONDO_0002049
MESH ID
D013921
UMLS CUI
C0040034
MedGen ID
52737
HPO ID
HP:0001873
SNOMED CT ID
302215000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 9 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AS-1670542 DMV05SW Approved Small molecular drug [1]
AST-120 DM718MD Approved Small molecular drug [2]
Bivalirudin DMECRX1 Approved Small molecular drug [3]
Eltrombopag DMOGFIX Approved Small molecular drug [4]
Lepirudin DM1I3D5 Approved Small molecular drug [5]
Lusutrombopag DMH6IKO Approved NA [1]
Oprelvekin DMTSRI6 Approved NA [6]
Romiplostim DM3U7SZ Approved Small molecular drug [7]
3,4-Dihydroxycinnamic Acid DMVZL26 Phase 4 Small molecular drug [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)
This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ALX-0081 DM7EBH9 Phase 3 NA [9]
Fostamatinib disodium DM3274D Phase 3 NA [10]
UNI-rhIL-11 DM0DIEZ Phase 3 NA [11]
VM-501 DM4P5UJ Phase 3 NA [12]
BI 655064 DMF86P2 Phase 2 Antibody [13]
Veltuzumab DM5BL4C Phase 2 Monoclonal antibody [10]
PRTX-100 DMF2XCC Phase 1/2 NA [13]
FT-1050-treated umbilical cord stem cell therapy DM0ABK3 Phase 1 NA [14]
NIP-004 DM0PYEQ Phase 1 NA [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)
This Disease is Treated as An Indication in 6 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
MDX-33 DMJ06Z8 Discontinued in Phase 2 NA [16]
HE2100 DMCP2KH Discontinued in Phase 1 Small molecular drug [17]
IDEC-131 DMAU79Q Discontinued in Phase 1 Antibody [18]
Totrombopag DM6SUDC Discontinued in Phase 1 Small molecular drug [19]
Antova DMXKZDU Terminated NA [20]
FR-128998 DMMOBHW Terminated NA [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 8 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Long-acting IL-11 analog DMGLLSC Investigative NA [2]
Non-peptide TPO mimics DMZ2DSK Investigative NA [22]
PEG-VM-501 DMNIYLD Investigative NA [2]
PG2-2000 DMMNLN5 Investigative NA [2]
SE-ET-TP020d DMCQNT9 Investigative NA [2]
STS-T4 DM5BATX Investigative NA [22]
ThromboMer DMRVXH7 Investigative NA [22]
TPO gene plasmid DMFL5XU Investigative NA [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 68 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCA1 TTJW1GN Limited Biomarker [25]
FCGR2A TTXT21W Limited Biomarker [26]
IL11 TTGUYTR Limited Biomarker [27]
NCR1 TTQNRJM Limited Biomarker [28]
PML TTLH9NY Limited Biomarker [29]
RARA TTW38KT Limited Biomarker [29]
SF3B1 TTL2WUI Limited Biomarker [30]
SPP1 TT8ME6I Limited Biomarker [31]
SRC TT6PKBN Limited Biomarker [32]
STAT1 TTN7R6K Limited CausalMutation [33]
THBD TTAPV67 Limited Altered Expression [34]
XDH TT7RJY8 Limited Biomarker [35]
ALB TTFNGC9 Disputed Biomarker [36]
CFH TTUW6OP moderate Biomarker [37]
IFNL3 TTRF4Q2 moderate Genetic Variation [38]
PTPRJ TTWMKXP moderate Biomarker [39]
SPARC TTBQFM7 moderate Biomarker [40]
APOH TT2OUI9 Strong Altered Expression [41]
ASGR1 TTYM94H Strong Posttranslational Modification [42]
CASP10 TTX5HEK Strong Biomarker [43]
CD209 TTBXIM9 Strong Genetic Variation [44]
CD36 TTPJMCU Strong Biomarker [45]
CDC20 TTBKFDV Strong Altered Expression [46]
CIT TT3BKTU Strong Genetic Variation [47]
CRLF2 TTRMZ0N Strong Biomarker [48]
CSF2 TTNYZG2 Strong Biomarker [49]
CSF3 TT5TQ2W Strong Biomarker [49]
CSF3R TTC70AJ Strong Genetic Variation [50]
DCPS TTLSW9V Strong Biomarker [51]
EPO TTQG4NR Strong Genetic Variation [52]
F2 TT6L509 Strong Biomarker [53]
FCER1G TTDGEC0 Strong Biomarker [54]
FCGRT TTKLPHO Strong Biomarker [55]
FGF4 TTCEKVZ Strong Biomarker [56]
FLNA TTSTRZY Strong Genetic Variation [57]
GBA TT1B5PU Strong Genetic Variation [58]
GGH TTZJRL0 Strong Genetic Variation [59]
GNE TT4DP5S Strong Genetic Variation [60]
GP1BA TTVB0Q9 Strong Genetic Variation [61]
HLA-A TTHONFT Strong Biomarker [62]
HLA-DQB2 TTL7VOU Strong Biomarker [63]
IFNA2 TTSIUJ9 Strong Biomarker [64]
ITGA2 TTSJ542 Strong Biomarker [65]
ITGB3 TTJA1ZO Strong Biomarker [66]
JAK1 TT6DM01 Strong Biomarker [67]
KIR2DS2 TTV3CFI Strong Biomarker [68]
KLK3 TTS78AZ Strong Biomarker [69]
MPL TTIHYA4 Strong Biomarker [70]
MTHFR TTQWOU1 Strong Biomarker [71]
NAAA TTMN4HY Strong Biomarker [72]
PECAM1 TT4EZB2 Strong Biomarker [73]
PNLIP TTXMY0J Strong Biomarker [74]
PRKCQ TT1MS7X Strong Genetic Variation [75]
PRKG1 TT7IZSA Strong Biomarker [76]
RNF34 TTEWDK1 Strong Biomarker [77]
S1PR4 TTZ8C5Q Strong Biomarker [78]
SELP TTE5VG0 Strong Altered Expression [79]
SLC17A5 TTFSUIA Strong Biomarker [80]
SLC29A1 TTLXAKE Strong Genetic Variation [81]
SLCO1B3 TTU86P0 Strong Biomarker [82]
TBXA2R TT2O84V Strong Genetic Variation [83]
THPO TTCG5PE Strong Altered Expression [84]
TNFRSF10A TT5WLRX Strong Biomarker [85]
TPO TT52XDZ Strong Biomarker [86]
TUBB1 TT63KYR Strong Genetic Variation [87]
WAS TTE8T73 Strong CausalMutation [60]
ADAMTS13 TTUREBK Definitive Biomarker [88]
UGT1A1 TT34ZAF Definitive Genetic Variation [89]
------------------------------------------------------------------------------------
⏷ Show the Full List of 68 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC25A10 DTJYKDQ Strong Biomarker [90]
SLC28A1 DT0EQPW Strong Genetic Variation [91]
------------------------------------------------------------------------------------
This Disease Is Related to 5 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
BAAT DERA3OF Strong Genetic Variation [92]
CYP2C8 DES5XRU Strong Biomarker [93]
GPT DER5HFI Strong Genetic Variation [94]
TPMT DEFQ8VO Strong Genetic Variation [95]
UBASH3B DE10BJ5 Strong Biomarker [96]
------------------------------------------------------------------------------------
This Disease Is Related to 95 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ASPG OT5E2EKR Limited Biomarker [97]
CDC42 OT5QBC5M Limited Genetic Variation [98]
GP9 OTA19OKO Limited Altered Expression [99]
ITGA2B OT4Y17PY Limited CausalMutation [60]
MPIG6B OTVNKQWA Limited Genetic Variation [100]
NBEAL2 OTMCAXWR Limited Genetic Variation [101]
RBM8A OT5SR6G0 Limited Genetic Variation [102]
SLFN14 OTMB4Y3R Limited Biomarker [103]
STIM1 OT8CLQ1W Limited Genetic Variation [104]
STX2 OTO2IDDR Limited Biomarker [34]
SERPINF2 OTZGAF8B Disputed Altered Expression [105]
ACTN1 OTUCLNXH moderate Genetic Variation [106]
CHRD OTNM60Y1 moderate Altered Expression [107]
GSC OT4DH7PR moderate Genetic Variation [107]
IL4I1 OTK54C63 moderate Biomarker [108]
MTX1 OTLSDNZO moderate Genetic Variation [109]
SH3BP4 OTVIRKW7 moderate Biomarker [110]
ANKRD26 OT2ENKKV Strong Genetic Variation [60]
ARHGEF40 OTFSKXG9 Strong Biomarker [111]
BCR OTCN76C1 Strong Biomarker [112]
BTBD8 OT3A3RD7 Strong Biomarker [113]
BTG3 OT9ANHVT Strong Biomarker [114]
C1GALT1 OT2ZSZ6P Strong Biomarker [115]
CACNB3 OTP30DIU Strong Biomarker [116]
CDAN1 OTCVZRG6 Strong Biomarker [117]
CHRNE OTGGXGGB Strong Genetic Variation [60]
CLEC1B OTO38TRG Strong Biomarker [118]
CLTA OTLHOXMQ Strong Genetic Variation [60]
CSN1S1 OTXOW6XJ Strong Biomarker [119]
CYCS OTBFALJD Strong Genetic Variation [60]
DDRGK1 OT3KCK0U Strong Genetic Variation [120]
DERL1 OTJUS74N Strong Genetic Variation [121]
EFNA5 OTOH4DRR Strong Genetic Variation [122]
EIF6 OTEXMUED Strong Biomarker [123]
EMP1 OTSZHUHQ Strong Genetic Variation [124]
ETV6 OTCZMG61 Strong Genetic Variation [125]
FBL OTRODIE5 Strong Biomarker [126]
FGA OTMIHY80 Strong Therapeutic [127]
FHL3 OTMPRLZ5 Strong Biomarker [128]
FLII OT7G9JG6 Strong Biomarker [129]
FUNDC2 OTY3TQM5 Strong Biomarker [130]
FYB1 OT6345CH Strong Biomarker [28]
GFI1B OTRDW8YO Strong Biomarker [131]
GGTLC1 OTWJKUHQ Strong Altered Expression [132]
GP1BB OTD7XNLL Strong Genetic Variation [60]
GP5 OT3WGPR3 Strong Biomarker [133]
GTF2I OTUYL1TQ Strong Genetic Variation [134]
GTF2IRD1 OTEG9KU1 Strong Genetic Variation [134]
HLA-DPA1 OT7OG7Y2 Strong Biomarker [115]
HLA-DRB3 OT5PM9N7 Strong Biomarker [135]
IFIH1 OTZA2AHA Strong CausalMutation [136]
IKZF5 OTJN51OC Strong Altered Expression [137]
IL3 OT0CQ35N Strong Therapeutic [138]
KDSR OTCIES3H Strong Genetic Variation [139]
LILRA3 OTBNQCOS Strong Altered Expression [140]
MAD2L1 OTXNGZCG Strong Altered Expression [46]
MASTL OTQ7YKK5 Strong Genetic Variation [141]
MCC OTQVI1EM Strong Genetic Variation [142]
MMS19 OTAXB34N Strong Biomarker [143]
MOCOS OT0TL3Q5 Strong Biomarker [144]
MPI OTBH6ZK1 Strong Altered Expression [145]
MT1E OTXJKU4Y Strong Biomarker [146]
MXI1 OTUQ9E0D Strong Altered Expression [46]
MYH9 OT94Z706 Strong Genetic Variation [147]
MYL9 OT6B22JB Strong Biomarker [148]
NFE2 OTLM94BI Strong Genetic Variation [149]
NIPBL OTF6OOLU Strong Genetic Variation [107]
OR2AG1 OTEITRP4 Strong Biomarker [150]
PIK3C2A OTFBU4GD Strong Altered Expression [151]
PLEK OTB73XXA Strong Biomarker [75]
PRAM1 OTZN3DWD Strong Biomarker [152]
PRB2 OTAD4JZ0 Strong Genetic Variation [153]
PRDX6 OTS8KC8A Strong Biomarker [154]
PRKACG OTKOQYF8 Strong Biomarker [155]
PRSS27 OTC4G4UF Strong Genetic Variation [156]
RASA3 OT9C54MN Strong Genetic Variation [157]
RASGRP1 OTX9WN2E Strong Biomarker [158]
RASGRP2 OTABVLVQ Strong Biomarker [158]
RHOF OTPA3F8Q Strong Biomarker [77]
RNPC3 OTW5MKC1 Strong Biomarker [159]
RO60 OTLGM5A8 Strong Biomarker [160]
SBF2 OTBB8NO8 Strong Genetic Variation [161]
SEPTIN5 OT6JTJBO Strong Genetic Variation [60]
SESTD1 OTHH06X8 Strong Biomarker [111]
SH2B2 OTEDHHDH Strong Biomarker [69]
SLURP1 OT89YD2E Strong Biomarker [51]
SMCP OTXKY794 Strong Biomarker [144]
SRSF2 OTVDHO6U Strong Biomarker [30]
STXBP2 OTX8GUC4 Strong Genetic Variation [162]
TCN2 OT41D0L3 Strong Biomarker [163]
TGS1 OTM79LML Strong Genetic Variation [164]
TNMD OTHLVA9G Strong Biomarker [165]
TRIM33 OT0KS4J7 Strong Biomarker [166]
LIG4 OT40DNXU Definitive CausalMutation [167]
MYH10 OTXN2WXS Definitive Biomarker [168]
------------------------------------------------------------------------------------
⏷ Show the Full List of 95 DOT(s)

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6961).
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6469).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6971).
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974).
8 ClinicalTrials.gov (NCT02556814) Caffeic Acid Combining High-dose Dexamethasone in Management of ITP. U.S. National Institutes of Health.
9 Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. J Cardiovasc Transl Res. 2013 Jun;6(3):355-63.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 ClinicalTrials.gov (NCT01663441) A Phase Study of Genetically Modified Recombinant Human Interleukin-11. U.S. National Institutes of Health.
12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033052)
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Clinical pipeline report, company report or official report of Fate therapeutics.
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027636)
16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007380)
17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015080)
18 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007783)
19 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010330)
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004313)
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2526).
24 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022291.
25 Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease).J Biol Chem. 2004 Aug 6;279(32):34032-7. doi: 10.1074/jbc.M405174200. Epub 2004 May 25.
26 Humanised effector-null FcRIIA antibody inhibits immune complex-mediated proinflammatory responses.Ann Rheum Dis. 2019 Feb;78(2):228-237. doi: 10.1136/annrheumdis-2018-213523. Epub 2018 Nov 20.
27 Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: A systematic review and meta-analysis.J Eval Clin Pract. 2020 Feb;26(1):262-271. doi: 10.1111/jep.13152. Epub 2019 Jun 20.
28 Immune Cell-Type Specific Ablation of Adapter Protein ADAP Differentially Modulates EAE.Front Immunol. 2019 Oct 1;10:2343. doi: 10.3389/fimmu.2019.02343. eCollection 2019.
29 Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia.Cancer Genet Cytogenet. 2005 Jun;159(2):129-36. doi: 10.1016/j.cancergencyto.2004.09.019.
30 Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.Leukemia. 2016 Mar;30(3):666-73. doi: 10.1038/leu.2015.304. Epub 2015 Oct 30.
31 Murine hematopoietic stem cell reconstitution potential is maintained by osteopontin during aging.Sci Rep. 2018 Feb 12;8(1):2833. doi: 10.1038/s41598-018-21324-x.
32 De novo variant in tyrosine kinase SRC causes thrombocytopenia: case report of a second family.Platelets. 2019;30(7):931-934. doi: 10.1080/09537104.2019.1628197. Epub 2019 Jun 17.
33 A novel presentation of homozygous loss-of-function STAT-1 mutation in an infant with hyperinflammation-A case report and review of the literature.J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):777-9. doi: 10.1016/j.jaip.2016.02.015. Epub 2016 Apr 23.
34 Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.J Immunol. 2011 Jul 1;187(1):172-80. doi: 10.4049/jimmunol.1100491. Epub 2011 Jun 3.
35 Role of free radicals in pulmonary thromboembolism in mice.Thromb Res. 1989 Sep 1;55(5):549-57. doi: 10.1016/0049-3848(89)90387-3.
36 Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.Gynecol Oncol. 2019 Feb;152(2):265-269. doi: 10.1016/j.ygyno.2018.11.024. Epub 2018 Nov 20.
37 Postdiarrhoeal haemolytic uraemic syndrome without thrombocytopenia.Nefrologia. 2017 Sep-Oct;37(5):508-514. doi: 10.1016/j.nefro.2016.12.009.
38 Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.World J Gastroenterol. 2015 May 28;21(20):6236-45. doi: 10.3748/wjg.v21.i20.6236.
39 Loss-of-function mutations in PTPRJ cause a new form of inherited thrombocytopenia.Blood. 2019 Mar 21;133(12):1346-1357. doi: 10.1182/blood-2018-07-859496. Epub 2018 Dec 27.
40 Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome.Chem Biol Interact. 2016 Dec 25;260:176-185. doi: 10.1016/j.cbi.2016.10.010. Epub 2016 Oct 8.
41 Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China.Lupus. 2019 Nov;28(13):1558-1565. doi: 10.1177/0961203319882506. Epub 2019 Oct 21.
42 Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein.Xenotransplantation. 2015 May-Jun;22(3):203-10. doi: 10.1111/xen.12164. Epub 2015 Feb 27.
43 Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa.Int J Immunogenet. 2011 Aug;38(4):287-93. doi: 10.1111/j.1744-313X.2011.01005.x. Epub 2011 Mar 7.
44 Association of promoter region polymorphisms of CD209 gene with clinical outcomes of dengue virus infection in Western India.Infect Genet Evol. 2013 Jul;17:239-42. doi: 10.1016/j.meegid.2013.04.024. Epub 2013 Apr 26.
45 Platelet Immunology in China: Research and Clinical Applications.Transfus Med Rev. 2017 Apr;31(2):118-125. doi: 10.1016/j.tmrv.2016.12.001. Epub 2016 Dec 6.
46 Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome.Leuk Res. 2018 Jan;64:61-70. doi: 10.1016/j.leukres.2017.11.013. Epub 2017 Nov 28.
47 2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.Blood Adv. 2018 Apr 10;2(7):754-761. doi: 10.1182/bloodadvances.2017013672.
48 CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.Leuk Res. 2016 Feb;41:36-42. doi: 10.1016/j.leukres.2015.11.018. Epub 2015 Dec 23.
49 Romiplostim (Nplate()) as an effective radiation countermeasure to improve survival and platelet recovery in mice.Int J Radiat Biol. 2020 Jan;96(1):145-154. doi: 10.1080/09553002.2019.1605465. Epub 2019 Apr 29.
50 ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.Am J Hematol. 2015 Jul;90(7):653-6. doi: 10.1002/ajh.24031.
51 A New Zealand White rabbit model of thrombocytopenia and coagulopathy following total body irradiation across the dose range to induce the hematopoietic-subsyndrome of acute radiation syndrome.Int J Radiat Biol. 2021;97(sup1):S19-S31. doi: 10.1080/09553002.2019.1668981. Epub 2020 Oct 5.
52 How does preeclampsia affect neonates? Highlights in the disease's immunity.J Matern Fetal Neonatal Med. 2019 Apr;32(7):1205-1212. doi: 10.1080/14767058.2017.1401996. Epub 2017 Nov 20.
53 Risk of complications of ultrasound-guided renal biopsy for adult and pediatric patients with systemic lupus erythematosus.Lupus. 2018 Apr;27(5):828-836. doi: 10.1177/0961203317751048. Epub 2018 Jan 4.
54 An (II)(b) (3) antagonist prevents thrombosis without causing Fc receptor -chain IIa-mediated thrombocytopenia.J Thromb Haemost. 2017 Nov;15(11):2230-2244. doi: 10.1111/jth.13803. Epub 2017 Oct 9.
55 The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.Blood. 2011 Dec 8;118(24):6403-6. doi: 10.1182/blood-2011-08-374223. Epub 2011 Oct 14.
56 Adenovirus-mediated transfer of HST-1/FGF-4 gene protects mice from lethal irradiation.Oncogene. 1999 Oct 21;18(43):5943-7. doi: 10.1038/sj.onc.1203171.
57 A novel truncating mutation in FLNA causes periventricular nodular heterotopia, Ehlers-Danlos-like collagenopathy and macrothrombocytopenia.Brain Dev. 2018 Jun;40(6):489-492. doi: 10.1016/j.braindev.2018.01.010. Epub 2018 Feb 12.
58 Thrombocytopenia and GBA gene mutation in a patient with adult type 1 Gaucher disease.Platelets. 2017 Dec;28(8):829-831. doi: 10.1080/09537104.2017.1306044. Epub 2017 Jun 5.
59 Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.Asian Pac J Cancer Prev. 2012;13(7):3461-4. doi: 10.7314/apjcp.2012.13.7.3461.
60 Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.Blood. 2019 Dec 5;134(23):2082-2091. doi: 10.1182/blood.2018891192.
61 Mechanisms of thrombocytopenia in platelet-type von Willebrand disease.Haematologica. 2019 Jul;104(7):1473-1481. doi: 10.3324/haematol.2018.200378. Epub 2019 Jan 17.
62 Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine. J Rheumatol. 1986 Apr;13(2):269-73.
63 Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria.Ann Rheum Dis. 1990 Aug;49(8):582-6. doi: 10.1136/ard.49.8.582.
64 Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.Cancer. 2004 Aug 1;101(3):596-603. doi: 10.1002/cncr.20403.
65 Platelet Function Changes during Neonatal Cardiopulmonary Bypass Surgery: Mechanistic Basis and Lack of Correlation with Excessive Bleeding.Thromb Haemost. 2020 Jan;120(1):94-106. doi: 10.1055/s-0039-1700517. Epub 2019 Nov 21.
66 Comparative evaluation of platelet counts in two hematology analyzers and potential effects on prophylactic platelet transfusion decisions.Transfusion. 2018 Oct;58(10):2301-2308. doi: 10.1111/trf.14886. Epub 2018 Sep 17.
67 Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.
68 KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.Pharmacogenomics J. 2017 Jul;17(4):360-365. doi: 10.1038/tpj.2016.19. Epub 2016 Mar 15.
69 Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients.Rheumatology (Oxford). 2021 Mar 2;60(3):1106-1113. doi: 10.1093/rheumatology/kez596.
70 Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2020 Mar;26(3):e65-e73. doi: 10.1016/j.bbmt.2019.12.003. Epub 2019 Dec 9.
71 Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Jun;50(6):912-7. doi: 10.1080/10428190902893819.
72 Analytical performance of automated platelet counts and impact on platelet transfusion guidance in patients with acute leukemia.Scand J Clin Lab Invest. 2019 May;79(3):160-166. doi: 10.1080/00365513.2019.1576100. Epub 2019 Feb 14.
73 A novel role for PECAM-1 in megakaryocytokinesis and recovery of platelet counts in thrombocytopenic mice.Blood. 2007 May 15;109(10):4237-44. doi: 10.1182/blood-2006-10-050740. Epub 2007 Jan 18.
74 Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon.Ther Adv Neurol Disord. 2017 Nov 29;11:1756285617741056. doi: 10.1177/1756285617741056. eCollection 2018.
75 Platelet protein kinase C-theta deficiency with human RUNX1 mutation: PRKCQ is a transcriptional target of RUNX1.Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):921-7. doi: 10.1161/ATVBAHA.110.221879. Epub 2011 Jan 20.
76 Protein kinase A activation by the anti-cancer drugs ABT-737 and thymoquinone is caspase-3-dependent and correlates with platelet inhibition and apoptosis.Cell Death Dis. 2017 Jun 29;8(6):e2898. doi: 10.1038/cddis.2017.290.
77 The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.Leuk Res. 2018 Feb;65:14-19. doi: 10.1016/j.leukres.2017.11.009. Epub 2017 Nov 15.
78 Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4.FASEB J. 2010 Dec;24(12):4701-10. doi: 10.1096/fj.09-141473. Epub 2010 Aug 4.
79 Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice.ACS Appl Mater Interfaces. 2019 Jan 9;11(1):244-254. doi: 10.1021/acsami.8b17625. Epub 2018 Dec 31.
80 Microangiopathic antiphospholipid antibody-associated syndrome in a pregnant lady.Lupus. 2017 Apr;26(4):435-437. doi: 10.1177/0961203316659548. Epub 2016 Jul 20.
81 Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.J Gastroenterol Hepatol. 2016 Aug;31(8):1489-97. doi: 10.1111/jgh.13290.
82 Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics. 2015;16(13):1439-50.
83 Platelet dysfunction caused by a novel thromboxane A(2) receptor mutation and congenital thrombocytopenia in a case of mild bleeding.Platelets. 2020;31(2):276-279. doi: 10.1080/09537104.2019.1652264. Epub 2019 Aug 7.
84 Plasma thrombopoietin levels as additional tool in clinical management of thrombocytopenic neonates.Platelets. 2020;31(1):62-67. doi: 10.1080/09537104.2019.1572877. Epub 2019 Feb 13.
85 Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3.
86 Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study.PLoS One. 2018 Feb 13;13(2):e0192271. doi: 10.1371/journal.pone.0192271. eCollection 2018.
87 TUBB1 dysfunction in inherited thrombocytopenia causes genome instability.Br J Haematol. 2019 Jun;185(5):888-902. doi: 10.1111/bjh.15835. Epub 2019 Mar 10.
88 The Association Between Human Leukocyte Antigens and ITP, TTP, and HIT.J Pediatr Hematol Oncol. 2019 Mar;41(2):81-86. doi: 10.1097/MPH.0000000000001381.
89 Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.Int J Clin Oncol. 2019 Mar;24(3):256-261. doi: 10.1007/s10147-018-1358-4. Epub 2018 Oct 17.
90 A Case Report and Literature Review of Scrub Typhus With Acute Abdomen and Septic Shock in a Child-The Role of Leukocytoclastic Vasculitis and Granulysin.Am J Dermatopathol. 2018 Oct;40(10):767-771. doi: 10.1097/DAD.0000000000001167.
91 Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer. 2009 Jan;63(1):121-7.
92 Comprehensive Platelet Phenotypic Laboratory Testing and Bleeding History Scoring for Diagnosis of Suspected Hereditary Platelet Disorders: A Single-Institution Experience.Am J Clin Pathol. 2017 Jul 1;148(1):23-32. doi: 10.1093/ajcp/aqx038.
93 Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.Arch Gynecol Obstet. 2019 Aug;300(2):395-407. doi: 10.1007/s00404-019-05197-7. Epub 2019 May 23.
94 Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.
95 Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.Pediatr Blood Cancer. 2011 Oct;57(4):578-82. doi: 10.1002/pbc.23013. Epub 2011 Feb 11.
96 TULA-2 (T-Cell Ubiquitin Ligand-2) Inhibits the Platelet Fc Receptor for IgG IIA (FcRIIA) Signaling Pathway and Heparin-Induced Thrombocytopenia in Mice.Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2315-2323. doi: 10.1161/ATVBAHA.116.307979. Epub 2016 Oct 20.
97 The sonographic appearance of cyclophosphamide-induced acute haemorrhagic cystitis.Clin Radiol. 1990 Apr;41(4):289-90. doi: 10.1016/s0009-9260(05)81670-8.
98 Further evidence of a mutation in CDC42 as a cause of a recognizable syndromic form of thrombocytopenia.Am J Med Genet A. 2016 Apr;170A(4):852-5. doi: 10.1002/ajmg.a.37526. Epub 2015 Dec 28.
99 A novel mutation in the GP1BA gene in Bernard-Soulier syndrome.Blood Coagul Fibrinolysis. 2020 Jan;31(1):83-86. doi: 10.1097/MBC.0000000000000868.
100 Novel G6B gene variant causes familial autosomal recessive thrombocytopenia and anemia.Eur J Haematol. 2017 Mar;98(3):218-227. doi: 10.1111/ejh.12819. Epub 2017 Jan 3.
101 NBEAL2 mutations and bleeding in patients with gray platelet syndrome.Platelets. 2018 Sep;29(6):632-635. doi: 10.1080/09537104.2018.1478405. Epub 2018 Jun 5.
102 The stability of Magoh and Y14 depends on their heterodimer formation and nuclear localization.Biochem Biophys Res Commun. 2019 Apr 9;511(3):631-636. doi: 10.1016/j.bbrc.2019.02.097. Epub 2019 Feb 27.
103 Role of the novel endoribonuclease SLFN14 and its disease-causing mutations in ribosomal degradation.RNA. 2018 Jul;24(7):939-949. doi: 10.1261/rna.066415.118. Epub 2018 Apr 20.
104 York platelet syndrome is a CRAC channelopathy due to gain-of-function mutations in STIM1.Mol Genet Metab. 2015 Mar;114(3):474-82. doi: 10.1016/j.ymgme.2014.12.307. Epub 2014 Dec 24.
105 Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.Circulation. 2014 Mar 25;129(12):1320-31. doi: 10.1161/CIRCULATIONAHA.113.006727. Epub 2014 Jan 21.
106 Novel ACTN1 variants in cases of thrombocytopenia.Hum Mutat. 2019 Dec;40(12):2258-2269. doi: 10.1002/humu.23840. Epub 2019 Nov 6.
107 Genomic organisation of the human chordin gene and mutation screening of candidate Cornelia de Lange syndrome genes.Hum Genet. 1999 Jul-Aug;105(1-2):104-11. doi: 10.1007/s004399900068.
108 Comparative proteomes, immunoreactivities and neutralization of procoagulant activities of Calloselasma rhodostoma (Malayan pit viper) venoms from four regions in Southeast Asia.Toxicon. 2019 Nov;169:91-102. doi: 10.1016/j.toxicon.2019.08.004. Epub 2019 Aug 22.
109 Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.Rheumatology (Oxford). 2020 Apr 1;59(4):709-717. doi: 10.1093/rheumatology/kez343.
110 Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.Crit Care Clin. 2015 Oct;31(4):661-74. doi: 10.1016/j.ccc.2015.06.004. Epub 2015 Aug 7.
111 Freedom SOLO-Associated Thrombocytopaenia is Valve-Dependent and Not Due to In Vitro Pseudothrombocytopaenia.Heart Lung Circ. 2017 Mar;26(3):268-275. doi: 10.1016/j.hlc.2016.07.002. Epub 2016 Aug 16.
112 Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.
113 Risk factors for mortality in elderly and very elderly critically ill patients with sepsis: a prospective, observational, multicenter cohort study.Ann Intensive Care. 2019 Feb 4;9(1):26. doi: 10.1186/s13613-019-0495-x.
114 Prevalence of autoimmune diseases and clinical significance of autoantibody profile: Data from National Institute of Hygiene in Rabat, Morocco.Hum Immunol. 2019 Jul;80(7):523-532. doi: 10.1016/j.humimm.2019.02.012. Epub 2019 Feb 23.
115 Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene.Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16442-7. doi: 10.1073/pnas.0607872103. Epub 2006 Oct 24.
116 The IIb p.Leu841Met (Cab3(a+) ) polymorphism results in a new human platelet alloantigen involved in neonatal alloimmune thrombocytopenia.Transfusion. 2013 Mar;53(3):554-63. doi: 10.1111/j.1537-2995.2012.03762.x. Epub 2012 Jun 28.
117 Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.Clin Cancer Res. 2019 Jul 1;25(13):3802-3810. doi: 10.1158/1078-0432.CCR-18-3964. Epub 2019 Feb 7.
118 Roles of the CLEC-2-podoplanin interaction in tumor progression.Platelets. 2018 Jun 4:1-7. doi: 10.1080/09537104.2018.1478401. Online ahead of print.
119 Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.J Clin Invest. 2005 Oct;115(10):2752-61. doi: 10.1172/JCI26007.
120 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.Hum Mol Genet. 2011 Sep 1;20(17):3507-16. doi: 10.1093/hmg/ddr249. Epub 2011 Jun 9.
121 Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.
122 AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia.Bioessays. 2000 Mar;22(3):214-8. doi: 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I.
123 Shwachman-Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability.Br J Haematol. 2019 Mar;184(6):974-981. doi: 10.1111/bjh.15729. Epub 2018 Dec 26.
124 Life-Threatening Thrombocytopenia Secondary to Trimethoprim/Sulfamethoxazole.Cureus. 2017 Dec 19;9(12):e1963. doi: 10.7759/cureus.1963.
125 Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia.Int J Lab Hematol. 2019 May;41 Suppl 1:131-141. doi: 10.1111/ijlh.12999.
126 Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.Antivir Ther. 2014;19(2):149-59. doi: 10.3851/IMP2686. Epub 2013 Sep 13.
127 Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).J Pharmacol Exp Ther. 1991 Mar;256(3):876-82.
128 Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3.J Med Genet. 2011 May;48(5):343-52. doi: 10.1136/jmg.2010.085456. Epub 2011 Jan 19.
129 Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 2000 Aug;13(2):167-77. doi: 10.1016/s1074-7613(00)00017-0.
130 Mitochondrial PIP3-binding protein FUNDC2 supports platelet survival via AKT signaling pathway.Cell Death Differ. 2019 Jan;26(2):321-331. doi: 10.1038/s41418-018-0121-8. Epub 2018 May 21.
131 T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice.Neuropsychopharmacology. 2019 Jul;44(8):1505-1512. doi: 10.1038/s41386-018-0300-9. Epub 2018 Dec 22.
132 Blood parameters in fetuses infected with cytomegalovirus according to the severity of brain damage and trimester of pregnancy at cordocentesis.J Clin Virol. 2019 Oct;119:37-43. doi: 10.1016/j.jcv.2019.08.008. Epub 2019 Aug 20.
133 Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.Haematologica. 2019 Jun;104(6):1237-1243. doi: 10.3324/haematol.2018.211086. Epub 2019 Mar 28.
134 De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia.Mol Psychiatry. 2012 Feb;17(2):142-53. doi: 10.1038/mp.2011.154. Epub 2011 Nov 15.
135 The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening.Blood. 1998 Oct 1;92(7):2280-7.
136 An extremely severe case of Aicardi-Goutires syndrome 7 with a novel variant in IFIH1.Eur J Med Genet. 2020 Feb;63(2):103646. doi: 10.1016/j.ejmg.2019.04.003. Epub 2019 Apr 6.
137 Germline mutations in the transcription factor IKZF5 cause thrombocytopenia. Blood. 2019 Dec 5;134(23):2070-2081. doi: 10.1182/blood.2019000782.
138 Further studies to ameliorate toxicity of carboplatin.Semin Oncol. 1994 Apr;21(2 Suppl 2):27-33; quiz 34, 58.
139 Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia.Haematologica. 2019 May;104(5):1036-1045. doi: 10.3324/haematol.2018.204784. Epub 2018 Nov 22.
140 The expression and clinical significance of different forms of LILRA3 in systemic lupus erythematosus.Clin Rheumatol. 2019 Nov;38(11):3099-3107. doi: 10.1007/s10067-019-04624-z. Epub 2019 Jun 17.
141 Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets.J Clin Invest. 2018 Dec 3;128(12):5351-5367. doi: 10.1172/JCI121876. Epub 2018 Oct 29.
142 Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.Pharmacogenet Genomics. 2017 Jul;27(7):270-274. doi: 10.1097/FPC.0000000000000286.
143 Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.PLoS One. 2012;7(10):e48350. doi: 10.1371/journal.pone.0048350. Epub 2012 Oct 31.
144 Clinical and equipment-related factors associated with the adequate peripheral blood stem cell collection in autologous transplant at a tertiary cancer center in Kerala - A retrospective cohort study.Transfus Apher Sci. 2019 Aug;58(4):457-463. doi: 10.1016/j.transci.2019.05.007. Epub 2019 Jun 21.
145 Carbohydrate-deficient glycoprotein syndrome type 1 with profound thrombocytopenia and normal phosphomannomutase and phosphomannose isomerase activities.J Pediatr. 1998 Nov;133(5):697-700. doi: 10.1016/s0022-3476(98)70115-5.
146 Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.
147 Identification of a Novel MYH9 Mutation in a Young Adult With Inherited Thrombocytopenia and Recurrent Seizures by Targeted Exome Sequencing.J Pediatr Hematol Oncol. 2020 Apr;42(3):e188-e192. doi: 10.1097/MPH.0000000000001430.
148 Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.Blood. 2010 Dec 23;116(26):6037-45. doi: 10.1182/blood-2010-06-289850. Epub 2010 Sep 27.
149 Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish.Blood Adv. 2018 Dec 11;2(23):3418-3427. doi: 10.1182/bloodadvances.2018021865.
150 Impact of Chemotherapy Regimens on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Rectal Cancer Patients Receiving Intensity Modulated Radiation Therapy With Concurrent Chemotherapy From a Prospective Phase III Clinical Trial.Front Oncol. 2019 Apr 9;9:244. doi: 10.3389/fonc.2019.00244. eCollection 2019.
151 Atypical neuroleptic malignant syndrome - A case report.Asian J Psychiatr. 2019 Jun;43:7-8. doi: 10.1016/j.ajp.2019.04.007. Epub 2019 Apr 30.
152 Acute promyelocytic leukemia relapsing into FAB-M2 acute myeloid leukemia with trisomy 8.Cancer Genet Cytogenet. 2000 Feb;117(1):82-3. doi: 10.1016/s0165-4608(99)00132-6.
153 A Novel Homozygous c.800C>G Substitution in GP1BA Exon 2 in a Kuwaiti Family with Bernard-Soulier Syndrome.Acta Haematol. 2015;134(3):193-8. doi: 10.1159/000381328. Epub 2015 May 28.
154 The role of peroxiredoxin 6 in neutralization of X-ray mediated oxidative stress: effects on gene expression, preservation of radiosensitive tissues and postradiation survival of animals.Free Radic Res. 2017 Feb;51(2):148-166. doi: 10.1080/10715762.2017.1289377. Epub 2017 Feb 22.
155 A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. Blood. 2014 Oct 16;124(16):2554-63. doi: 10.1182/blood-2014-01-551820. Epub 2014 Jul 24.
156 Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.Hematology. 2019 Dec;24(1):516-520. doi: 10.1080/16078454.2019.1631509.
157 The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin IIb3 Outside-in Signaling.J Biol Chem. 2017 Feb 3;292(5):1691-1704. doi: 10.1074/jbc.M116.746867. Epub 2016 Nov 30.
158 CalDAG-GEFI deficiency protects mice in a novel model of Fc RIIA-mediated thrombosis and thrombocytopenia.Blood. 2011 Jul 28;118(4):1113-20. doi: 10.1182/blood-2011-03-342352. Epub 2011 Jun 7.
159 The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients.Asian Pac J Allergy Immunol. 2021 Dec;39(4). doi: 10.12932/AP-211218-0465.
160 Thrombocytopenia in the neonatal lupus syndrome.Arch Dermatol. 1988 Apr;124(4):560-3.
161 Identification of a novel SBF2 missense mutation associated with a rare case of thrombocytopenia using whole-exome sequencing.J Thromb Thrombolysis. 2013 Nov;36(4):501-6. doi: 10.1007/s11239-012-0864-x.
162 Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.Arthritis Rheumatol. 2020 Feb;72(2):326-334. doi: 10.1002/art.41103. Epub 2019 Dec 26.
163 Human uncoupling protein 2 and 3 genes are associated with obesity in Japanese.Endocrine. 2008 Aug-Dec;34(1-3):87-95. doi: 10.1007/s12020-008-9111-9. Epub 2008 Oct 28.
164 Clinical significance of lnc-AC145676.2.1-6 and lnc-TGS1-1 and their variants in western Chinese tuberculosis patients.Int J Infect Dis. 2019 Jul;84:8-14. doi: 10.1016/j.ijid.2019.04.018. Epub 2019 Apr 24.
165 An audit of the diagnostic accuracy of rotational thromboelastometry for the identification of hypofibrinogenaemia and thrombocytopenia during cardiopulmonary bypass.Anaesth Intensive Care. 2018 Nov;46(6):620-626. doi: 10.1177/0310057X1804600614.
166 Purinergic ecto-enzymes participate in the thromboregulation in acute in mice infection by Trypanosoma cruzi.Mol Cell Biochem. 2017 Aug;432(1-2):1-6. doi: 10.1007/s11010-017-2992-2. Epub 2017 Mar 11.
167 Extreme growth failure is a common presentation of ligase IV deficiency.Hum Mutat. 2014 Jan;35(1):76-85. doi: 10.1002/humu.22461. Epub 2013 Nov 8.
168 MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.Blood. 2012 Sep 27;120(13):2719-22. doi: 10.1182/blood-2012-04-422352. Epub 2012 Jun 7.